Latest News
May 02, 2012
Webcast link for Q1 2012 results
April 16, 2012
Annual Report 2011
March 13, 2012
Intercell starts a pivotal Phase II/III efficacy study with its Pseudomonas aeruginosa vaccine candidate
March 01, 2012
Intercell starts the second part of a Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections
January 11, 2012
Intercell and Statens Serum Institut (SSI) progress vaccine clinical development to fight Tuberculosis
December 30, 2011
Thomas Szucs elected new chairman of Intercell’s Supervisory Board
November 10, 2011
Intercell and Biological E. Ltd. announce approval for Japanese Encephalitis vaccine in India
November 08, 2011
Intercell AG announces Q3 2011 results and provides an update on ongoing operations
November 03, 2011
Webcast link for Q3 2011 results
October 24, 2011
Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections
October 12, 2011
Intercell receives positive scientific advice from EMA for Pseudomonas vaccine Phase II/III-study
September 29, 2011
EU invests €30 million to boost vaccine research
September 22, 2011
NEW Company Presentation
September 16, 2011
Intercell and Biological E. Ltd. announce successful completion of investigational Japanese Encephalitis vaccine pivotal Phase II/III study in India
August 16, 2011
Intercell announces Q2 and H1 2011 financial results and provides an update on execution of strategic plan
August 10, 2011